NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.